Business Wire

Celltrion Healthcare Present 1-year Results for CT-P13 (Biosimilar Infliximab, Remsima®/ Inflectra®) Switching Study in Crohn’s Disease

Del

Today at the 25th United European Gastroenterology Week Congress, Celltrion Healthcare presented data from the phase III, randomised controlled, switching trial comparing CT-P13 and reference infliximab. The data showed comparable efficacy and safety between all treatment groups (maintained and switched) in patients with moderate to severe Crohn’s disease (CD) up to one year.1

The trial investigated the efficacy and safety of CT-P13 throughout a 54-week treatment period, following a switch from reference infliximab at week 30. 220 patients were randomly assigned to four groups (maintained groups [CT-P13 and reference infliximab] and switched groups [reference infliximab to CT-P13 and CT-P13 to reference infliximab]) in a double-blinded manner. Efficacy, pharmacokinetics (PK) and safety were comparable among all treatment groups up to week 30.2 The Crohn’s Disease Activity Index - 70 (CDAI-70) response, clinical remission and the Short Inflammatory Bowel Disease questionnaire (SIBDQ) score, a measure of quality of life for people with inflammatory bowel disease, were similar among all groups at each measured time point up to week 54 too.1

The safety profiles among all treatment groups, including adverse reactions, serious adverse events, infections, and immunogenicity were similar throughout the one year treatment period.1

Professor Stefan Schreiber, Director of the Clinic for Internal Medicine at Kiel Campus of the University Hospital Schleswig-Holstein in Germany, commented on the study, “This is the next randomised controlled trial following the NOR-SWITCH study in patients with inflammatory bowel disease using CT-P13 infliximab that shows positive results. All treatment groups in this study, including reference infliximab maintenance, CT-P13 infliximab maintenance, and switching in both directions (reference to CT-P13 and CT-P13 to reference) groups showed comparable efficacy and safety. As a gastroenterologist, I find these data reassuring and hope they help my fellow physicians make informed treatment decisions to ensure the best outcomes for their patients.”

Improving patient treatment experience of CT-P13

Celltrion Healthcare also presented data from an initial phase I open label study of a subcutaneous (SC) form of CT-P13 in healthy volunteers. The study was designed to evaluate the safety and PK of CT-P13 SC. Results showed PK profiles after a single SC injection were linear by dose levels. Subcutaneous administration of CT-P13 was found to be feasible in terms of bioavailability and safety profile and could provide patients with a more convenient and accessible treatment administration option.3

Man Hoon Kim, President and CEO of Celltrion Healthcare, said, “Active switching to biosimilars could have a significant impact on the financial sustainability of healthcare systems by generating budget savings for biologic treatments. This switching study in Crohn’s disease is important in showing clinical evidence of the comparable safety and efficacy when switching to biosimilars. Adding to the wealth of data for CT-P13, Celltrion Healthcare is confident that these results should help physicians to feel even more confident in switching between reference products and biosimilars and is committed to continuously providing more convenient treatment options, including the subcutaneous form of infliximab to patients.”

Notes to editors:

About inflammatory bowel disease

Inflammatory bowel diseases (IBD), including Crohn’s disease (CD) and ulcerative colitis (UC), are chronic disabling gastrointestinal disorders that impact every aspect of a patient’s life.4 They affect an estimated 2.5-3 million people in Europe;5 CD affects about three people per 1,000 and UC about 5 people per 1,000.4

IBDs account for substantial costs to the healthcare system and society; the direct healthcare costs of IBDs are estimated to be €4.6-5.6 billion per year.5

About Celltrion Healthcare

Celltrion Healthcare conducts the worldwide marketing, sales and distribution of biological medicines developed by Celltrion, Inc. through an extensive global network that spans more than 120 different countries. Celltrion Healthcare’s products are manufactured at state-of-the-art mammalian cell culture facilities, designed and built to comply with the US Food and Drug Administration (FDA) cGMP guidelines and the EU GMP guidelines. For more information please visit: http://www.celltrionhealthcare.com/.

About CT-P13 3.4 CD RCT

The study is a randomised, double-blind, parallel-group, phase III study to investigate the efficacy and safety of CT-P13 compared to reference infliximab in people with Crohn’s disease. Out of 220 patients randomised in 58 study centres across 16 countries, 214 patients completed up to week 6 for the primary analysis and 180 patients completed up to week 30. At week 30 approximately half of the patients in each group were switched to the alternative treatment up to 54 weeks. 166 patients completed the study to 54 weeks. The study was funded equally by Celltrion and Pfizer.

About CT-P13 (biosimilar infliximab)

CT-P13 is developed and manufactured by Celltrion, Inc. and was the world’s first monoclonal antibody biosimilar approved by the European Medicines Agency (EMA). It is indicated for the treatment of eight autoimmune diseases including rheumatoid arthritis and IBD. It was approved by the EMA under the trade name Remsima® in September 2013 and launched in Europe in early 2015. The US FDA approved CT-P13 in April 2016 under the trade name Inflectra™. CT-P13 is approved in more than 80 countries (as of October 2017) including the US, Canada, Japan and throughout Europe.

1 Kim YH, et al. LB04, Phase III randomized controlled trial to compare biosimilar infliximab (CT-P13) with innovator infliximab in patients with active Crohn’s disease: 1-year maintenance and switching results. Presented at the 25th United European Gastroenterology Week Congress.
2 Kim YH, et al. Phase III randomized double-blinded, controlled trial to compare biosimilar infliximab (CT-P13) with innovator infliximab (INX) in patients with active Crohn’s disease: early efficacy and safety results. Gastroenterology 152, S65 (2017).
3 R. Westhovens et al . P0387, Subcutaneous administration of a novel formulation of CT-P13 (Infliximab biosimilar) is safe and achieves projected therapeutic drug levels: a phase Ⅰ study in healthy subjects, Presented at the 25th United European Gastroenterology Week Congress.
4 Molodecky NA, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012; 142(1)46–54. Available at www.gastrojournal.org/article/S0016-5085(11)01378-3/pdf [Last accessed January 2017].
5 Burisch J, et al. The burden of inflammatory bowel disease in Europe. Journal of Crohn's and Colitis (2013)7,322-337.

Contact information

For Celltrion Healthcare:
Emma Gorton, +44 203 817 6591
egorton@hanovercomms.com
or
Suru Douglas, +44 203 817 6586
sdouglas@hanovercomms.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

MobileIron Recognized as a Partner in Google Led Android Enterprise Recommended Program for Enterprise Mobility Management Providers15.1.2019 17:20Pressemelding

MobileIron (NASDAQ:MOBL), the secure foundation for modern work, today announced that it has been recognized by Google™ as a partner in its Android Enterprise Recommended program for Enterprise Mobility Management (EMM) providers. Android™ Enterprise Recommended validates those EMM solutions that meet an elevated set of requirements defined by Google, delivering advanced Android Enterprise features that are supported by highly knowledgeable teams specializing in modern Android security and management. “Enterprise transformation will be central to the second decade of Android computing. Offerings like Android Enterprise Recommended, OEM Config, and Google Play Protect create the perfect storm to support the millions of Android devices that are increasingly making their way to the enterprise,” said Simon Biddiscombe, CEO, MobileIron. “MobileIron is pleased to be a partner in the Android Enterprise Recommended program for EMMs. We are confident that our expertise in endpoint and device se

INDYCAR Names NTT as Entitlement Sponsor of IndyCar Series15.1.2019 17:20Pressemelding

INDYCAR announced today during the North American International Auto Show that global information technology and communications leader NTT has signed a multi-year agreement to become the IndyCar Series Title Partner. In addition, NTT becomes the Official Technology Partner of INDYCAR, the IndyCar® Series, Indianapolis Motor Speedway, the Indianapolis 500 and NASCAR’s the Brickyard 400 beginning in 2019. INDYCAR will partner with NTT to deliver digital innovations that enhance the fan experience. These innovations include the evolution of INDYCAR’s mobile application and adoption of NTT’s proprietary Smart Platform to support the sport and its venues in delivering better insights into the racing series. “NTT is proud to be associated with INDYCAR and accelerate the future of smart racing. Technological innovations have the potential to change the sport and fan experience drastically,” said Jun Sawada, President and CEO of NTT. “NTT, along with our partners, aims to bring the Smart World

CSC Extends Fund Administration Reach into Asia Pacific15.1.2019 15:00Pressemelding

CSC has extended their private equity and real estate fund administration services into Asia. Third-party oversight of private equity and real estate funds is increasing due to the growing demand from investors for greater transparency and help navigating the regulatory requirements in this dynamic landscape. “A number of factors are creating opportunities in the private equity market in Asia, including strong deal growth, increasing reporting demands from investors, and pressure to commit unspent capital,” says Bill Popeo, president of CSC’s Global Financial Markets business. Liam McHugh, Fund Administration managing director, is leading the efforts in Asia, with office locations in Singapore, Hong Kong, and Shanghai. Prior to joining CSC, McHugh served in various executive capacities at Apex Fund Services and Equinoxe Alternative Investment Services in the APAC region and Ireland. “CSC’s private ownership status ensures the stability that is required of a service provider in a fragme

UAEREP’s First Cycle Awardees Present Outstanding Final Project Results At the 3rd IREF15.1.2019 14:29Pressemelding

The UAE Research Program for Rain Enhancement Science’s 3rd International Rain Enhancement Forum (IREF) today featured the final project results of its 1st Cycle awardees at the 2019 Abu Dhabi Sustainability Week (ADSW). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190115005523/en/ 3rd International Rain Enhancement Forum Reveals Results of the Researches of its First Cycle (Photo: AETOSWire) In the presence of a distinguished audience of VIP dignitaries, diplomats, stakeholders and scientists, Dr Linda Zou, Professor Volker Wulfmeyer, Professor Masataka Murakami, presented the final results of innovative research advancing rain enhancement science in the UAE and beyond. The three awardees that presented the successful outcomes of original research projects completed within a 3-year time scale are: Professor Linda Zou, a Professor at the Khalifa Institute of Science and Technology, has fabricated, tested and validated nove

Enterprises Will Increase Digital Technology Investment and Adoption in 2019 According to Study by Economist Intelligence Unit and DXC Technology15.1.2019 14:00Pressemelding

A vast majority of businesses will increase their investments in digital technology over the coming year, and many expect IT modernization to fuel future transformation efforts that lead to cost savings and greater profitability. These are some of the findings from a new global survey conducted by The Economist Intelligence Unit (EIU) and commissioned by DXC Technology (NYSE: DXC), the world’s leading independent, end-to-end IT services company. The study, “2019: The Year of Digital Decisions,” explores how companies define digital transformation and the resulting business outcomes. Significantly, the report reveals that more than eight in ten survey respondents (83 percent) expect their organizations to increase their digital investments in 2019. And more than 40 percent of respondents predict that their organizations will increase their investments by 11 percent or more. Currently, approximately half of companies surveyed have digitally enabled just three key organizational functions

TDK's Subsidiary TDK-Lambda Uses Transphorm GaN to Advance PFH Series AC-DC Power Supply15.1.2019 13:00Pressemelding

Transphorm Inc.—the leader in the design and manufacturing of the highest reliability and only qualified high-voltage (HV) Gallium Nitride (GaN) semiconductors—today confirmed that leading power supply manufacturer TDK-Lambda, a group company of TDK, has released its first GaN-based AC-DC power supply. The full function 504 W rated PFH500F-28 is the company’s latest generation AC-DC baseplate cooled power supply module. Further, the power module is the latest Transphorm customer product to demonstrate the HV GaN advantages, increasing efficiency by 5 percent in a 28 percent smaller package over the previous PFE500F series. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190115005041/en/ TDK-Lambda's PFH500F-28 AC-DC power supply module uses Transphorm's GaN modules for a 30% power density increase. (Graphic: Business Wire) Broad Industrial Applications Get a Boost The PFH500F-28 is a low-profile power module with 28 volts of